Health Canada Authorizes a 200-Participant Psilocybin Trial as Regulators Focus on Practitioner Training

Canada's clinical psilocybin research is about to scale up. On September 23, 2026, Optimi Health, a British Columbia-based licensed producer, announced that it has completed manufacturing the psilocybin supply for a Health Canada-authorized Phase 2 clinical trial in major depressive disorder (MDD). The trial, first announced on September 10, will enrol up to 200 participants across multiple Canadian sites, making it one of the largest psilocybin studies ever planned in this country.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334.

The timing is notable. Nine days earlier, on September 14, the U.S. Food and Drug Administration held a landmark public hearing on the future therapeutic use of psychedelic drugs, and one of the dominant themes was the need for standardized, competency-based training for every member of the care team. Together, these developments point to a clear message for Canadian healthcare practitioners: the infrastructure for psychedelic-assisted therapy is being built now, and a trained workforce is central to it.

What was announced

According to the company's September 10 release, Health Canada has authorized a multisite, open-label Phase 2 trial evaluating the safety and efficacy of a single supervised dose of naturally derived psilocybin, delivered within a psilocybin-assisted therapy model, for adults with MDD. The primary endpoint is change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The company expects to initiate the trial in the first half of 2027, complete dosing by the end of 2027, and report topline results after all follow-up evaluations are finished.

The September 23 update confirms that a single cGMP batch of 5 mg psilocybin capsules has been produced end-to-end at the company's Princeton, B.C. facility under its Health Canada Drug Establishment Licence. The same batch is being used to supply licensed clinics in Australia, where psilocybin can be prescribed for treatment-resistant depression under that country's Authorised Prescriber Scheme. In Canada, the company notes that its products are accessible only through Health Canada's case-by-case authorization pathway, initiated by a physician.

A few caveats are worth stating plainly. This is a company announcement, not a peer-reviewed publication. The trial is open-label, meaning there is no placebo comparison, which limits what it can tell us about efficacy. And no results exist yet; dosing has not begun. What the announcement does establish is that Health Canada has authorized a substantial domestic trial, and that Canadian-manufactured psilocybin is now being produced at commercial scale under federal licensing.

Why it matters for Canadian practitioners

Outside of clinical trials, the only legal pathway to psilocybin-assisted therapy in Canada remains Health Canada's case-by-case authorization, initiated by a physician. Under Health Canada's 2023 notice to stakeholders, a request must come from a practitioner licensed to prescribe in their province or territory, must document that conventional treatments have failed, are unsuitable, or are unavailable for the patient's serious or life-threatening condition, and must be supported by evidence of safety and efficacy for that specific patient. Practitioners must also comply with their provincial or territorial regulatory body and report adverse reactions through Canada Vigilance.

That framework keeps access narrow, but it also means every such authorization depends on clinicians who understand screening, preparation, supervised dosing, and integration well enough to justify and manage treatment. A 200-participant trial spread across multiple Canadian sites will need the same skills at scale: study nurses, psychologists, physicians, and therapists who can support participants through a full treatment episode. Trials of this size are, in effect, a training ground for the field.

The regulatory conversation is now about people, not just molecules

The FDA's September 14 hearing drew more than 18,000 registrants and roughly 80 selected speakers from academia, patient groups, providers, and industry, with federal partners including the Veterans Health Administration and the Substance Abuse and Mental Health Services Administration on the panel. Summaries published by U.S. law firms on September 16 and 18 describe four recurring themes: provider training and credentialing, patient safety, access and reimbursement, and data standardization.

On training, speakers argued that requirements should cover the entire patient-care episode, from screening through integration, and should be competency-based rather than tied to a single discipline. Commentators stressed that all healthcare team members, not just prescribers, should demonstrate proficiency in core competencies, and that clear roles are needed across nurses, facilitators, pharmacists, and other professionals. Several speakers also emphasized that patient safety extends well beyond the pharmacological intervention, with onsite monitoring lasting several hours described as critical to outcomes. At least one speaker called for any Risk Evaluation and Mitigation Strategy to be proportionate and not overly prescriptive, and one commenter characterized reimbursement as a safety question, because without it, clinics will close. Written comments are open until October 5, 2026.

The U.S. backdrop matters for Canada because of what comes next. Compass Pathways has reported that its two Phase 3 trials of COMP360 psilocybin in treatment-resistant depression enrolled more than 1,000 participants, and the company is submitting a rolling New Drug Application with final submission expected in the fourth quarter of 2026. The FDA granted the program a Commissioner's National Priority Voucher in April, which the company says allows for an accelerated one- to two-month review after filing. BioSpace reported on September 14 that the candidate is widely expected to receive a decision by the end of this year or in early 2027. If that happens, Canadian regulators, colleges, and clinics will face immediate questions about training standards, supervision models, and access that the FDA hearing has already begun to map.

What this means for practitioners considering training

Three practical takeaways emerge from this week's news.

First, clinical capacity in Canada is expanding through research before it expands through approval. A domestic Phase 2 trial of this size, alongside the existing authorization pathway, creates near-term demand for practitioners who can work within regulated, supervised protocols.

Second, competency is being defined as a team standard. The FDA hearing made clear that nurses, therapists, and pharmacists, not only prescribers, are expected to demonstrate proficiency across preparation, administration, and follow-up. Provincial colleges in Canada are likely to draw on the same logic.

Third, the evidence base is still maturing. Open-label Phase 2 data will need to be interpreted cautiously, and even Phase 3 results should be read as findings about specific populations and protocols rather than guarantees for any individual patient.

For healthcare professionals who want to be prepared as this field develops, ATMA CENA's Advanced Pathways offer complete, mostly online programs that begin with the Psychedelic Therapy Foundations course and build toward regulated clinical practice, with an in-person KAT Immersive option in Calgary. If you are weighing whether this training fits your practice, you can explore the programs at the psychedelic therapy training page or book a call with a program advisor to talk through your questions.

Sources

1. Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply. GlobeNewswire, 2026.
2. Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder. GlobeNewswire, 2026.
3. Health Canada notice to stakeholders: requests involving psychedelic-assisted psychotherapy. Health Canada, 2023.
4. Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing (09/14/2026). U.S. Food and Drug Administration, 2026.
5. Summary and Key Takeaways from FDA's September 2026 Public Hearing on Psychedelic Drugs. UBC Insights, 2026.
6. FDA Holds Landmark Public Hearing on the Future Therapeutic Use of Psychedelic Drugs. Mondaq (Foley Hoag LLP), 2026.
7. Psychedelic therapies ride wave of public favor into FDA hearing. BioSpace, 2026.
8. Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher. Compass Pathways, 2026.
9. Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile. Compass Pathways, 2026.